Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dosing Device Paradigm Shifts For Liquid OTCs In Wake Of Safety Concerns

This article was originally published in The Tan Sheet

Executive Summary

OTC drug manufacturers must consider a dosing device as a primary element of liquid product packaging to improve consumer safety through proper dosing, industry stakeholders say

You may also be interested in...



ScripsAmerica Launches RapiMed To Beat Tylenol Meltaways

ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.

ScripsAmerica Launches RapiMed To Beat Tylenol Meltaways

ScripsAmerica Inc.’s new RapiMed line of orally dissolving pediatric painkillers seeks to beat McNeil Consumer Healthcare’s Tylenol Meltaways’ return to the market and steal share from private label by promising to melt faster, taste better and cost less. The products also address FDA dosing concerns and target Hispanic shoppers.

FDA Gets Strict On Liquid OTC Dosing Devices In Draft Guidance

Pediatric medicine dosing is a key driver for the guidance, which clarifies that when a dosing device fails "to bear markings consistent with the labeled dosage directions," the drug is misbranded.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel